NEW YORK (GenomeWeb News) – Qiagen has completed its acquisition of SABiosciences, a privately held developer of disease- and pathway-focused PCR assay panels, for around $90 million.

Qiagen announced the deal in early November, saying at that time that it expects SABiosciences' products to be highly synergistic with its September acquisition of UK-based companion diagnostics firm DxS.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.